EU/3/19/2183

About

On 25 July 2019, orphan designation EU/3/19/2183 was granted by the European Commission to Voisin Consulting S.A.R.L., France, for mavorixafor for the treatment of WHIM syndrome.

Key facts

Active substance
Mavorixafor
Disease / condition
Treatment of WHIM syndrome
Date of first decision
25/07/2019
Outcome
Positive
EU designation number
EU/3/19/2183

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Voisin Consulting S.A.R.L.
64 Avenue Pierre Grenier
92100 Boulogne-Billancourt
France
Tel. +33 1413 18300
E-mail: orphan@voisinconsulting.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating
Average
1 rating